Document is current
Any future updates will be listed below
-
Authors
Anijärv, Toomas Erik https://orcid.org/0000-0002-3650-4230
Ossenkoppele, Rik https://orcid.org/0000-0003-1584-7477
Smith, Ruben https://orcid.org/0000-0001-7147-0112
Pichet Binette, Alexa https://orcid.org/0000-0001-5218-3337
Collij, Lyduine E. https://orcid.org/0000-0001-6263-1762
Behjat, Harry H. https://orcid.org/0000-0001-6729-6801
Rittmo, Jonathan https://orcid.org/0000-0001-5075-0166
Karlsson, Linda https://orcid.org/0000-0002-0630-772X
Ahmadi, Khazar https://orcid.org/0000-0002-3371-6211
Strandberg, Olof
,
Weiner, Michael
Aisen, Paul
Petersen, Ronald
Jack, Clifford R. Jr.
Jagust, William
Landau, Susan
Rivera-Mindt, Monica
Okonkwo, Ozioma
Shaw, Leslie M.
Lee, Edward B.
Toga, Arthur W.
Beckett, Laurel
Harvey, Danielle
Green, Robert C.
Saykin, Andrew J.
Nho, Kwangsik
Perrin, Richard J.
Tosun, Duygu
van Westen, Danielle https://orcid.org/0000-0001-8649-9874
Vogel, Jacob W. https://orcid.org/0000-0001-6394-9940
Stomrud, Erik
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Mattsson-Carlgren, Niklas https://orcid.org/0000-0002-8885-7724
Spotorno, Nicola https://orcid.org/0000-0001-5404-8788
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
- License Information
-
More Information
Article History
Received: 14 April 2025
Accepted: 20 August 2025
First Online: 5 September 2025
Competing interests
: O.H. is an employee of Eli Lilly and Lund University. R.S. has received consultancy/speaker fees from Eli Lilly, Novo Nordisk, Roche and Triolab. S.P. has acquired research support (for the institution) from ki elements / ADDF and Avid. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Esai, Eli Lilly, Novo Nordisk, and Roche. N.M.C. has received consultancy/speaker fees from Biogen, Eli Lilly, Owkin, and Merck. The precursor of [18F]flutemetamol was sponsored by GE Healthcare. The other authors declare no competing interests.
